Abstract
Twenty-eight children with beta-thalassaemia major aged between 11 and 48 months were given intensive transfusions. Serum iron, transferrin saturation, serum ferritin, non-transferrin iron, and subcutaneous desferrioxamine-induced urinary iron excretion were measured. The results showed that even children with a limited number of transfusions had severe iron overload as indicated, in particular, by the raised serum ferritin levels and the high excretion rates after subcutaneous infusion of desferrioxamine. The desferrioxamine test was useful, even in very young children, in assessing response to chelation therapy thus enabling such treatment to be started early to prevent harm from iron overload.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barry M., Flynn D. M., Letsky E. A., Risdon R. A. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J. 1974 Apr 6;2(5909):16–20. doi: 10.1136/bmj.2.5909.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Batey R. G., Lai Chung Fong P., Shamir S., Sherlock S. A non-transferrin-bound serum iron in idiopathic hemochromatosis. Dig Dis Sci. 1980 May;25(5):340–346. doi: 10.1007/BF01308057. [DOI] [PubMed] [Google Scholar]
- Hershko C., Graham G., Bates G. W., Rachmilewitz E. A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978 Oct;40(2):255–263. doi: 10.1111/j.1365-2141.1978.tb03662.x. [DOI] [PubMed] [Google Scholar]
- Hoffbrand A. V., Gorman A., Laulicht M., Garidi M., Economidou J., Georgipoulou P., Hussain M. A., Flynn D. M. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet. 1979 May 5;1(8123):947–949. doi: 10.1016/s0140-6736(79)91721-5. [DOI] [PubMed] [Google Scholar]
- Huisman T. H., Schroeder W. A., Brodie A. N., Mayson S. M., Jakway J. Microchromatography of hemoglobins. II. A simplified procedure for the determination of hemoglobin A2. J Lab Clin Med. 1975 Oct;86(4):700–702. [PubMed] [Google Scholar]
- Letsky E. A. A controlled trial of long-term chelation therapy in homozygous beta-thalassemia. Birth Defects Orig Artic Ser. 1976;12(8):31–41. [PubMed] [Google Scholar]
- Modell B., Letsky E. A., Flynn D. M., Peto R., Weatherall D. J. Survival and desferrioxamine in thalassaemia major. Br Med J (Clin Res Ed) 1982 Apr 10;284(6322):1081–1084. doi: 10.1136/bmj.284.6322.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Modell C. B., Beck J. Long-term desferrioxamine therapy in thalassemia. Ann N Y Acad Sci. 1974;232(0):201–210. doi: 10.1111/j.1749-6632.1974.tb20586.x. [DOI] [PubMed] [Google Scholar]
- Pippard M. J., Letsky E. A., Callender S. T., Weatherall D. J. Prevention of iron loading in transfusion-dependent thalassaemia. Lancet. 1978 Jun 3;1(8075):1178–1181. doi: 10.1016/s0140-6736(78)90968-6. [DOI] [PubMed] [Google Scholar]
- Propper R. D., Button L. N., Nathan D. G. New approaches to the transfusion management of thalassemia. Blood. 1980 Jan;55(1):55–60. [PubMed] [Google Scholar]
- Propper R. D., Cooper B., Rufo R. R., Nienhuis A. W., Anderson W. F., Bunn H. F., Rosenthal A., Nathan D. G. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977 Aug 25;297(8):418–423. doi: 10.1056/NEJM197708252970804. [DOI] [PubMed] [Google Scholar]
- Propper R. D., Shurin S. B., Nathan D. G. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med. 1976 Jun 24;294(26):1421–1423. doi: 10.1056/NEJM197606242942603. [DOI] [PubMed] [Google Scholar]
- SINGER K., CHERNOFF A. I., SINGER L. Studies on abnormal hemoglobins. I. Their demonstration in sickle cell anemia and other hematologic disorders by means of alkali denaturation. Blood. 1951 May;6(5):413–428. [PubMed] [Google Scholar]